WO2009051151A1 - Ｔｒｐｖ１媒介性疾患治療剤 - Google Patents

Ｔｒｐｖ１媒介性疾患治療剤 Download PDF

Info

Publication number
WO2009051151A1
WO2009051151A1 PCT/JP2008/068696 JP2008068696W WO2009051151A1 WO 2009051151 A1 WO2009051151 A1 WO 2009051151A1 JP 2008068696 W JP2008068696 W JP 2008068696W WO 2009051151 A1 WO2009051151 A1 WO 2009051151A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
trpv1
alkyl group
mediated disease
therapeutic agent
Prior art date
Application number
PCT/JP2008/068696
Other languages
English (en)
French (fr)
Inventor
Kenji Oki
Fumio Tsuji
Chikako Setoguchi
Iwao Seki
Masaaki Murai
Minoru Sasano
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Priority to CN2008801117250A priority Critical patent/CN101827816B/zh
Priority to ES08839876T priority patent/ES2431344T3/es
Priority to EP08839876.3A priority patent/EP2210878B1/en
Priority to CA2702455A priority patent/CA2702455A1/en
Priority to PL08839876T priority patent/PL2210878T3/pl
Priority to KR1020107009774A priority patent/KR101518525B1/ko
Priority to US12/682,090 priority patent/US20100261911A1/en
Publication of WO2009051151A1 publication Critical patent/WO2009051151A1/ja
Priority to US13/680,465 priority patent/US8901155B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

　本発明は、一般式［Ｉ］で表される構造を有するウレア化合物の新たな薬理作用を見出すことを課題とする。一般式［Ｉ］で表される構造を有するウレア化合物またはその塩類は、優れたＴＲＰＶ１媒介性疾患治療作用を有する。式中、Ａは低級アルキレン基または低級アルケニレン基を示し、；Ｒ１は水素原子、アルキル基またはアルケニル基を示し、該アルキル基およびアルケニル基は任意の置換基で置換されていてもよく；Ｒ２およびＲ３は同一または異なって水素原子または低級アルキル基を示し、該低級アルキル基は単環式のシクロアルキル基、多環式のシクロアルキル基またはアリール基で置換されていてもよい。
PCT/JP2008/068696 2007-10-16 2008-10-16 Ｔｒｐｖ１媒介性疾患治療剤 WO2009051151A1 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN2008801117250A CN101827816B (zh) 2007-10-16 2008-10-16 Trpv1介导性疾病治疗剂
ES08839876T ES2431344T3 (es) 2007-10-16 2008-10-16 Agente terapéutico para la vejiga hiperactiva
EP08839876.3A EP2210878B1 (en) 2007-10-16 2008-10-16 Therapeutic agent for overactive bladder
CA2702455A CA2702455A1 (en) 2007-10-16 2008-10-16 Therapeutic agent for trpv1-mediated disease
PL08839876T PL2210878T3 (pl) 2007-10-16 2008-10-16 Środek terapeutyczny przeciwko nadaktywnemu pęcherzowi
KR1020107009774A KR101518525B1 (ko) 2007-10-16 2008-10-16 Ｔｒｐｖ1 매개성 질환 치료제
US12/682,090 US20100261911A1 (en) 2007-10-16 2008-10-16 Therapeutic agent for trpv1-mediated disease
US13/680,465 US8901155B2 (en) 2007-10-16 2012-11-19 Method for treating a TRPV1-mediated disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-268785 2007-10-16
JP2007268785 2007-10-16

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/682,090 A-371-Of-International US20100261911A1 (en) 2007-10-16 2008-10-16 Therapeutic agent for trpv1-mediated disease
US13/680,465 Division US8901155B2 (en) 2007-10-16 2012-11-19 Method for treating a TRPV1-mediated disease

Publications (1)

Publication Number Publication Date
WO2009051151A1 true WO2009051151A1 (ja) 2009-04-23

Family

ID=40567414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/068696 WO2009051151A1 (ja) 2007-10-16 2008-10-16 Ｔｒｐｖ１媒介性疾患治療剤

Country Status (9)

Country Link
US (2) US20100261911A1 (ja)
EP (2) EP2210878B1 (ja)
JP (2) JP5512948B2 (ja)
KR (1) KR101518525B1 (ja)
CN (1) CN101827816B (ja)
CA (1) CA2702455A1 (ja)
ES (1) ES2431344T3 (ja)
PL (1) PL2210878T3 (ja)
WO (1) WO2009051151A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049082B1 (en) 2013-09-24 2019-05-22 Purdue Pharma L.P. Treatment of burn pain by trpv1 modulators
US10899702B2 (en) 2015-02-07 2021-01-26 University of Pittsburgh—of the Commonwealth System of Higher Education HTRPVI chemical agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002053555A (ja) 2000-05-31 2002-02-19 Santen Pharmaceut Co Ltd ＴＮＦ−α産生阻害物質
JP2003226686A (ja) 2001-11-30 2003-08-12 Santen Pharmaceut Co Ltd 血管新生阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003236247A1 (en) * 2002-05-03 2003-11-17 Warner-Lambert Company Llc Bombesin antagonists
WO2003097586A1 (en) * 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
CA2542494A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
AP2008004432A0 (en) * 2005-10-07 2008-04-30 Glenmark Pharmaceuticals Sa Substituted benzofused derivatives and their use as vanilloid receptor ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002053555A (ja) 2000-05-31 2002-02-19 Santen Pharmaceut Co Ltd ＴＮＦ−α産生阻害物質
JP2003226686A (ja) 2001-11-30 2003-08-12 Santen Pharmaceut Co Ltd 血管新生阻害剤

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
AHLUWALIA ET AL., EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 17, 2003, pages 2611
ANDERSON ET AL., FED. PROC., vol. 18, 1959, pages 412
DAI Y. ET AL.: "Capsaicin Juyotai no Yakuwari", IGAKU NO AYUMI, vol. 211, no. 5, 2004, pages 389 - 392, XP008141109 *
DAI, T.; NOGUCHI, K.; IGAKU NO AYUMI, JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 211, no. 5, 2004, pages 389 - 392
FOLIA PHARMACOLOGICA JAPONICA, vol. 129, no. 5, pages 361 - 373
HARADA N. ET AL., PROGRESS IN MEDICINE, vol. 22, 2002, pages 1997
HOSHINO ET AL., FOLIA PHARMACOLOGICA JAPONICA, vol. 97, 1991, pages 287
IGAKU NO AYUMI, JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 195, no. 9, 2000, pages 582 - 584
JAPANESE JOURNAL OF PHARMACOLOGY, vol. 57, 1991, pages 205
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 267, pages 728 - 733
KATO S. ET AL., G.I. RESEARCH, vol. 13, 2005, pages 367
KATO, S. ET AL., G.I. RESEARCH, vol. 13, 2005, pages 367
KUO, H. ET AL., THE JOURNAL OF UROLOGY, vol. 176, 2006, pages 641 - 645
KUO, H-C. ET AL.: "Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study.", J UROL., vol. 176, no. 2, 2006, pages 641 - 645, XP024990505 *
LABOUR; WELFARE: "Guideline for Clinical Evaluation Methods of Drugs for Overactive Bladder", NOTIFICATION NO. 0628001 OF THE PHARMACEUTICAL AFFAIRS AND FOOD SANITATION COUNCIL OF THE MINISTRY OF HEALTH
MASUDA N. ET AL.: "Hainyo Shogai Chiryoyaku no Kiso", FOLIA PHARMACOLOGICA JAPONICA, vol. 129, no. 5, 14 May 2007 (2007-05-14), pages 361 - 367, XP008141111 *
MURAI, M. ET AL.: "SA13353 (1-[2-(1-Adamantyl) ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea) inhibits TNF-a production through the activation of capsaicin-sensitive afferent neurons mediated via transient receptor potential vanilloid 1 in vivo", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 588, no. 2-3, 7 July 2008 (2008-07-07), pages 309 - 315, XP022712039 *
PHELPS ET AL., EUR. J. PHARMACOL., vol. 513, 2005, pages 57 - 66
RASHID H. ET AL., THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 304, 2003, pages 940
SOMMER, C. ET AL.: "Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy", BRAIN RESEARCH, vol. 913, no. 1, 2001, pages 86 - 89, XP002249717 *
TADAHITO SHIMADA ET AL.: "Shokakan Nenmaku Shogai to Cytokine", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 56, no. 9, 1998, pages 27.2235 - 31.2239, XP008141110 *
TAMURA S. ET AL.: "Tsukaku Dentatsu ni Okeru Enshosei Cytokine no Yakuwari", IGAKU NO AYUMI, vol. 211, no. 5, 2004, pages 393 - 397, XP008141112 *
WATKINS, L. R. ET AL.: "Beyond neurons: evidence that immune and glial cells contribute to pathological pain states", PHYSIOL. REV., vol. 82, 2002, pages 981 - 1011, XP008133468 *
YU ET AL., JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 290, 1999, pages 825
ZHANG, J-H. ET AL.: "The immune system: a new look at pain", CLIN.MED., vol. 119, no. 11, 2006, pages 930 - 938, XP008134054 *
ZIMMERMANN, M. ET AL.: "Pathobiology of neuropathic pain", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 429, no. ISSUES, 2001, pages 23 - 37, XP008133255 *

Also Published As

Publication number Publication date
KR20100080550A (ko) 2010-07-08
ES2431344T3 (es) 2013-11-26
US8901155B2 (en) 2014-12-02
PL2210878T3 (pl) 2014-01-31
JP5512948B2 (ja) 2014-06-04
CN101827816A (zh) 2010-09-08
JP2014148519A (ja) 2014-08-21
CN101827816B (zh) 2013-05-08
EP2210878A4 (en) 2010-12-01
EP2210878B1 (en) 2013-07-31
EP2666767A1 (en) 2013-11-27
EP2210878A1 (en) 2010-07-28
JP5853043B2 (ja) 2016-02-09
CA2702455A1 (en) 2009-04-23
US20130090359A1 (en) 2013-04-11
US20100261911A1 (en) 2010-10-14
JP2009114182A (ja) 2009-05-28
KR101518525B1 (ko) 2015-05-15

Similar Documents

Publication Publication Date Title
WO2008111441A1 (ja) 医薬組成物
MY152972A (en) Azabicyclo compound and salt thereof
WO2008114817A1 (ja) 新規なアデニン化合物
MY172034A (en) Intermediate for producing bicyclic ?-amino acid derivative
WO2008146871A1 (ja) グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体
WO2008111239A1 (ja) 帯電防止剤およびその用途
EP2845587A3 (en) Melanin production inhibitor
MX2009013728A (es) Derivados de bicicloanilina.
MY150507A (en) Polycyclic compound
MY148703A (en) Polycyclic cinnamide derivatives
EA200870336A1 (ru) Полициклические производные циннамида
SG10201809895YA (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
WO2009044788A1 (ja) ベンゾオキサジノン誘導体
ECSP099073A (es) Nuevos derivados de piridazina
EP1845081A4 (en) amide
WO2008120759A1 (ja) ウレア化合物およびその用途
WO2009057079A3 (en) Novel pyrimidine derivatives
WO2007066784A3 (en) Diarylether derivatives as antitumor agents
WO2007033039A3 (en) Proteasome inhibiting beta lactam compounds
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
WO2008114812A1 (ja) Jak阻害剤
WO2008078762A1 (ja) ウレア構造を有する新規ｎ－(２－アミノフェニル)ベンズアミド誘導体
GB0412769D0 (en) Organic compounds
WO2008078725A1 (ja) チアゼピン誘導体
MX2014000937A (es) Compuesto de amidina o sal del mismo.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880111725.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08839876

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12682090

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2702455

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008839876

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107009774

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: JP